

## Special Issue

# Curative Therapies for Non-Small Cell Lung Cancer

### Message from the Guest Editor

On behalf of *Cancers*, I would like to announce a call for articles for a Special Issue entitled “Curative Therapies for Non-Small Cell Lung Cancer”. In this rapidly changing world of lung cancer therapeutics, we are seeing patients live much longer lives. At *Cancers*, we recognize that during the last decade, we have observed a remarkable increase in patient survival due to the better selection and refinement of techniques for surgery and radiotherapy, as well as the growing armamentarium of systemic therapies including tyrosine kinase inhibitors for actionable mutations, immunotherapy with or without chemotherapy, and anti-angiogenic therapy combined with immunotherapy. We will be considering all options for “curative” therapy, including neo-adjuvant/adjuvant therapy for resectable disease, treatments for locally advanced disease, local therapies for oligometastatic disease (de novo, recurrent or persistent), as well as the long-term curative potential of systemic therapies.

### Guest Editor

Dr. John Michael Varlotto

Department of Oncology, Marshall University Chief of Radiation Oncology, Edwards Comprehensive Cancer Center, Huntington, WV, USA

### Deadline for manuscript submissions

closed (30 April 2025)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/177443](https://mdpi.com/si/177443)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)